Sensitization and reversal of MDR by silibinin

2012-11-07 classification: efficacy 0 people commented that Tyagi AK and other silybin and adriamycin jointly act on DU145 cells, resulting in significant synergistic effect Compatibility index (CI) is often used as one of the criteria to evaluate drug interactions CL < 1 indicates that the two drugs have synergistic effects The results showed that Ci was 0.552, Ci was 0.173 and Ci was 0.364 for 48 hours The results showed that the two drugs had obvious synergistic effect Compared with any single drug, the combination of the two drugs causes stronger G2 / M phase arrest and apoptosis Dhanalakshmi s et al [223 treated DU145 cells with sb and cisplatin Compared with cisplatin alone, the combination of the two can significantly inhibit cell growth The growth inhibition rate of cisplatin alone was 68%, while that of s alone was 80% ~ 90% At the same time, G2 / M phase arrest and apoptosis, Caspase-3, 7, 9 activation, cdc2, cyclin B1, cdc25c decreased significantly Tyagi AK et al Found that silibinin combined with adriamycin, cisplatin and carboplatin could inhibit the proliferation of estrogen dependent and independent breast cancer MCF-7 and mda-mb468 cells, and had significant apoptosis, the combined index was less than 0.8, showing synergistic effect One of the important reasons for the failure of tumor chemotherapy is the resistance to a series of chemotherapy drugs with different structures and functions, i.e multidrug resistance (MDR) P-glycoprotein (P-BP) - mediated resistance is one of its important mechanisms Zhang s et al found that SM could increase the accumulation of daunorubicin in MCF-7 and mda435alcc6 cells with high P-gp expression and multidrug-resistant phenotype, which showed a double dependence of sb concentration and P-gp positive; SM could also increase the toxicity of adriamycin in P-gp high expression cells; The results showed that SM decreased the P-gp labeled by [3H] - azizonone, suggesting that SM interacted directly with the P-gp substrate Multidrug resistance associated protein-1 (MRP-1), like P-gp, belongs to the ABC membrane transporter superfamily, which is involved in the development of drug resistance with P-gp Nguyen et al Found that silymarin (SM) can significantly increase the accumulation of daunorubicin and vinblastine in PANC-1 cell line with high expression of MRP-1, but it has no effect on the expression of MRP-1 and S-transferase of gufugan skin The mechanism may be that silymarin (SM) directly interacts with MRP-1 and changes the level of gufugan skin in cells BCRP is a newly discovered drug-resistant protein in breast cancer, which is also involved in MDR Cooray et al Found that silymarin (SM) can increase the accumulation of mitoonion ketone (the natural substrate of BCRP) in BCRP overexpression cells, and its degree is in direct proportion to the positive rate of BCRP expression.